Research-informed guides and practical strategies, so you don't have to figure this out alone.
New Insights into Pediatric HS Treatment Delays & Potential for Low-Dose Ertapenem
Read full briefingWhether you were just diagnosed, looking for the latest treatments, or seeking community - we have you covered.
Understand what HS is, why it happens, and what your first steps should be.
Biologics, JAK inhibitors, clinical trials, and the latest HS drug pipeline explained clearly.
Common HS experiences, caregiver resources, and a community that understands.
Get our free resource pack and stay up to date on the latest HS research.
HS Survival Starter Kit
Practical first steps for the newly diagnosed
Weekly Research Briefings
New studies from PubMed and clinical trials
Evidence-Informed Guides
Diet, wound care, and treatment options
Community Updates
New content alerts and community news
No spam, ever. Unsubscribe anytime.
The most important developments in HS research right now - explained clearly for patients.
#01
Newer biologics targeting IL-17 inflammation pathways - including secukinumab and bimekizumab - are showing strong Phase-3 results with promising reductions in abscesses and nodules.
Why it matters:HS is increasingly being treated as an immune system disease, not just a skin problem.
#02
JAK inhibitors like povorcitinib are showing reductions in lesions and pain for moderate-to-severe HS in Phase-3 trials - offering a pill-based alternative to biologics.
Why it matters:Many patients prefer oral medication over injections.
#03
Scientists are discovering that IL-1 inflammation signaling plays a role in HS. Experimental monoclonal antibodies like LAD191 and IL-1 blocking therapies show early promise.
Why it matters:It opens an entirely new therapeutic pathway for HS.
#04
Researchers are mapping immune pathways in individual patients - cytokine patterns, genetic markers, and immune signaling profiles - paving the way for precision dermatology.
Why it matters:Future HS treatment may become customized for each patient.
#05
New research suggests starting biologics earlier in moderate HS may slow disease progression - a shift from the traditional approach of using them only after other treatments fail.
Why it matters:Earlier treatment may prevent severe tunnels, scarring, and repeated surgeries.
#06
New studies show promising results combining biologic drugs with surgery - biologics reduce inflammation while surgical removal of tunnels leads to better long-term outcomes.
Why it matters:HS may require multi-layered treatment strategies for long-term control.
In 2025 alone, nearly 1,000 HS studies were published and dozens of clinical trials launched worldwide - exploring microbiome changes, immune dysregulation, hormonal influence, and metabolic inflammation.
Why it matters:For decades HS was neglected. That is finally changing.
Daily briefings, weekly deep-dives, a live clinical trial tracker, and the full HS drug pipeline - all in one place.
A February 2026 study found that 54% of HS patients on GLP-1 receptor agonists experienced less severe disease after six months, with 52% reporting less pain and 53% less drainage. Here is what the latest research shows and what it means for patients.
New research summaries, patient guides, and community resources added regularly.
Sonelokimab, an IL-17A/F nanobody from MoonLake Immunotherapeutics, achieved HiSCR75 in 42% of patients in the VELA Phase 3 trial, with a strong safety profile and a BLA submission pathway now underway. Here is what HS patients need to know about this advanced pipeline biologic.
Two-year data from the BE HEARD trials published in February 2026 showed that more than 85% of initial bimekizumab responders maintained their improvements, with 90% sustaining HiSCR50 and 86% maintaining quality of life gains. Here is what the long-term data means for patients.
A February 2026 study found that 54% of HS patients on GLP-1 receptor agonists for six months experienced less severe disease, with 52% reporting less pain and 53% less drainage. Here is what patients and clinicians need to know about this emerging treatment connection.
Get the latest HS research, treatment news, and practical guides delivered to your inbox. No spam - just the information that matters.
No spam, ever. Unsubscribe anytime.